Fortress Biotech, Inc.
- Last sale
- Nov 12, 2026 · -1.00%
- Market cap
- $66.65M
- 33.49M shares
- Filings
- 888
Q3 2026+9.7% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY24 yoy
Q3 2026N/M FY25 yoy
Q3 2026+38.6% FY25 yoy
- $66.65M
- 0.7×
- 1.0×
- 0.4×
- —
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of record
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $63,262,000 | reported | |
| FY 2024 | 2024-12-31 | $57,675,000 | reported | |
| FY 2023 | 2023-12-31 | $84,513,000 | reported | |
| FY 2022 | 2022-12-31 | $75,743,000 | reported | |
| FY 2021 | 2021-12-31 | $68,791,000 | reported | |
| FY 2020 | 2020-12-31 | $45,599,000 | reported | |
| FY 2019 | 2019-12-31 | $36,629,000 | reported | |
| FY 2018 | 2018-12-31 | $26,882,000 | reported | |
| FY 2017 | 2017-12-31 | $17,245,000 revised | reported | |
| FY 2016 | 2016-12-31 | $16,480,000 | reported | |
| FY 2015 | 2015-12-31 | $863,000 | reported | |
| FY 2014 | 2014-12-31 | $0 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $664.00K | — | $664.00K | — | 31.36M sh | +12.4% | — |
| FY2024 | $694.00K | — | $694.00K | — | 27.91M sh | +84.9% | — |
| FY2023 | $736.00K | — | $736.00K | — | 15.09M sh | +104.9% | — |
| FY2022 | $749.00K | — | $749.00K | — | 7.37M sh | −92.7% | — |
| FY2021 | $749.00K | — | $749.00K | — | 101.44M sh | +6.9% | — |
Segments
LineFY2025ShareChange
Journey$61.86M98%+10.2%
Avenue$1.40M2.2%—
Checkpoint Merger———
Dermatology Products Sales———
Fortress———
Pharmaceutical and Biotechnology Product Development———
Total$63.26M
Pharmaceutical preparations
Fortress Biotech, Inc. is the 119th largest of the 554 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
VRDNViridian Therapeutics, Inc.$70.8M23,359.9%483.6%$3.5BRMTIRockwell Medical, Inc.$69.3M31.8%7.7%$29.6MKURAKura Oncology, Inc.$67.5M25.2%412.9%$682.7MENTAEnanta Pharmaceuticals Inc$65.3M3.4%125.4%$325.8M
FBIOFortress Biotech, Inc. (this company)$63.3M9.7%10.8%$66.3M
NUVBNuvation Bio Inc.$62.9M699.0%325.3%$1.4BTNGXTango Therapeutics, Inc.$62.4M48.3%162.9%$4.2BDERMJourney Medical Corp$61.9M10.2%18.5%$123.4MAYTUAytu Biopharma, Inc$57.6M13.3%24.8%$19.4MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Fortress Biotech, Inc. · CIK 1429260 · Engraved from SEC EDGAR